Lv64
2300 积分 2024-12-03 加入
T-cell engagers in rheumatology
3天前
求助中
Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate
5天前
已完结
Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives
6天前
已完结
Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions
17天前
已完结
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
17天前
已完结
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
1个月前
已完结
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas
1个月前
已完结
Revisiting VEGF/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?
1个月前
已完结
Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020–2025)
1个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
皖公网安备34019202002308
